Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
• Treatments: Ethiodized Oil; Oxaliplatin; Raltitrexed

Criteria

Inclusion Criteria:

1. Histologically confirmed colorectal adenocarcinoma

2. Disease limited to the liver Unresectable disease by surgery or other local therapies

3. Age >18 years

4. ECOG performance status 0-2,Child pugh A or B

5. Expected survival ≥ 3 months

6. Adequate hematological, hepatic, and renal function

Exclusion Criteria:

1. Pregnant or lactating women

2. Patients with severe organ dysfunction or failure

3. With severe cardiovascular disease, or mental

4. Extraliver metastases